News Release

19/01/2021

OncoHost Secures $8 Million Series B Funding Round to Advance its AI-Powered Precision Oncology Platform

On a Mission to Match Individual Cancer Patients with the Most Effective Treatment, Investment will Expand Clinical Trials, Support Opening of a US Office and Preparation for Commercial Launch

Read More>
Cision

11/01/2021

OncoHost Welcomes Nobel Prize Winner to Scientific Advisory Board

Prof. Aaron Ciechanover Joins Host Response Profiling Company to Improve Precision Oncology and Overcome Resistance to Cancer Treatments

Read More>
Cision

09/11/2020

OncoHost to Present Data on Predicting Host Response to Immunotherapy in Melanoma Patients at SITC 2020

Study Examines Plasma-Based Proteomic Profiling as a Clinically Insightful Tool for Oncologists to Identify New Targets in Overcoming Treatment Resistance

Read More>
Cision

05/10/2020

OncoHost to Present Data on Predicting Host Response to Immunotherapy at the MAP 2020 Virtual Congress – ESMO

Presentation to Focus on Host Response to Newly Approved Immune Checkpoint Inhibitors (ICIs) and How These Host Effects May Stratify Between Non-Small Cell Lung Cancer (NSCLC) Patients' Responsiveness to Immunotherapy.

Read More>
Cision

17/09/2020

OncoHost to Present Data on Host Response Profiling for NSCLC Patients at ESMO Virtual Congress 2020

Clinical Study Investigates Host Response-Related Biological Processes that Relate to Immunotherapy Treatment Resistance in NSCLC Patients

Read More>
Cision

14/05/2020

OncoHost to Present Data on Host Response Profiling for Melanoma Patients at 2020 ASCO Annual Meeting

patients. ASCO's annual meeting is taking place from May 29-June 2 online due to COVID-19. About OncoHost OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of

Read More>
Cision

21/01/2020

OncoHost and RayBiotech Awarded $1 Million Grant From the BIRD Foundation to Advance Precision Oncology for Patients Receiving Immunotherapy

cancer patients." "The grant and support from the BIRD Foundation represents an important milestone for OncoHost," said Dr. Ofer Sharon, CEO of OncoHost. "We are committed to develop a system for the early identification of resistance to cancer therapy in patients

Read More>
Cision

21/01/2020

BIRD – Israel-U.S. Binational Industrial R&D Foundation to Invest $8 million in 9 New Projects

Boise, ID) to develop a cyber security solution to prevent and monitor persistent attacks on connected media devices. OncoHost (Binyamina, Israel) and RayBiotech Life (Peachtree Corners, GA) to develop

Read More>
Cision

04/12/2019

OncoHost Opens First-of-its-Kind Proteomics Laboratory for Host Response Analysis for Cancer Therapy

Sharon, MD, CEO of OncoHost. "By combining OncoHost's proprietary technology with proteomic analysis, we are able to predict how individual patients may respond to treatment. This is the first step towards developing successful personalized cancer treatment plans." OncoHost has launched an extensive

Read More>
Cision

31/10/2019

OncoHost: Nature Reviews Cancer Article Outlines Host Response Analysis as New Tool for Precision Medicine in Oncology

Studying Host Response to Cancer Therapies Offers New Direction for Clinical Priority in Patient Cancer Care

Read More>
Cision